ArticleAngiogenesis2026
ATP-citrate lyase is a critical regulator of physiological and pathological angiogenesis.
Article in Angiogenesis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Reconsidering the metabolic specificity of ACLY-dependent angiogenesis.Angiogenesis · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
Sprouting angiogenesis requires endothelial cells (ECs) to transition into specialized tip and stalk cells, a process influenced by metabolic regulation. ATP-citrate lyase (ACLY), which generates acetyl-CoA from citrate, is markedly activated in proliferating ECs (PECs) but less so in quiescent ECs (QECs). However, it remains elusive whether ACLY-derived acetyl-CoA fuels angiogenesis. Here, we demonstrate the critical role of ACLY in angiogenesis. ACLY depletion impaired EC proliferation, migration, tube formation, and sprouting, while EC-specific Acly-knockout mice showed reduced physiological and pathological angiogenesis, including in oxygen-induced retinopathy (OIR). Mechanistically, ACLY fuels glycolysis, boosts acetyl-CoA production, and enhances histone acetylation at key angiogenic gene loci. Intriguingly, acetate supplementation restored acetyl-CoA levels and rescued defective angiogenesis in ACLY-deficient models. In addition, pharmacological inhibition of ACLY suppressed neovascularization in OIR models. These findings establish ACLY as a previously unrecognized metabolic and epigenetic regulator of angiogenesis, highlighting its potential as a therapeutic target for pathological neovascularization.
Indexed as
Identifiers
41781787What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.